Careful review of these more recently-published trials in other health conditions, and characterization of putative contributors to disparate results, would be useful prior to embarking on any future trials of intranasal insulin in people with MS in order to maximize the capacity to detect a treatment effect, if one exists. The gene discussed is INS; the disease is myeloid sarcoma.